Abstract
Cancer-immunotherapy-focused Forty Seven has launched with $75 million in its first round of financing. Forty Seven has licensed the rights to patents covering Hu5F9-G4, a humanized monoclonal antibody against CD47, and other immuno-oncology targets and antibodies. Three Stanford University researchers identified CD47 as an attractive cancer target in 2009 and have since put Hu5F9-G4 into two Phase I studies in people with acute myeloid leukemia or solid tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
